KRAS and cancer: These data support the proposal that inhibition of KRAS4A can increase sensitivity to a subset of known cancer therapeutics in vitro, but further in-depth screening using small molecule libraries or CRISPR/Cas9 approaches will be required to identify vulnerabilities that may be dependent on variations in KRAS4A/KRAS4B levels.